Casdin Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Casdin Capital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$607K	Hold	165,323	–	–	0.03%	41
2026 Q1	$508K	Hold	165,323	–	–	0.04%	38
2025 Q4	$676K	Hold	165,323	–	–	0.04%	36
2025 Q3	$807K	Hold	165,323	–	–	0.07%	28
2025 Q2	$837K	Hold	165,323	–	–	0.08%	28
2025 Q1	$875K	Hold	165,323	–	–	0.07%	38
2024 Q4	$1.12M	Buy	+165,323	New	+$1.11M	0.07%	35
2022 Q2	–	Sell	-548,156	Closed	-$3.92M	–	47
2022 Q1	$3.92M	Hold	548,156	–	–	0.18%	44
2021 Q4	$9.39M	Hold	548,156	–	–	0.26%	45
2021 Q3	$12.6M	Hold	548,156	–	–	0.31%	42
2021 Q2	$20M	Buy	+548,156	New	+$16.2M	0.51%	37

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Casdin Capital's RXRX Position: Q2 2026 in Review

Casdin Capital held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 165,323 shares worth $607K. The position accounts for 0.03% of the portfolio, ranked #41.

Casdin Capital first reported a position in RXRX in Q2 2021 and has held it in 11 quarters since. The position peaked at $20M in Q2 2021. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Casdin Capital held 165,323 shares of Recursion Pharmaceuticals worth $607K as of Q2 2026.
Casdin Capital left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up 0.03% of Casdin Capital's portfolio in Q2 2026, its #41 holding.
Casdin Capital first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
Casdin Capital's Recursion Pharmaceuticals position peaked at $20M in Q2 2021.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Casdin Capital's 13F filing for Q2 2026, filed 14 Aug 2026.